Latecomer Hilleman Looks To Leverage Cholera Vaccine Advantages

Hilleman Laboratories' CEO believes the Indian venture’s oral cholera vaccine could become the best in its class, telling Scrip cost-effectiveness is critical amid growing budgetary strains and outlining plans for a convenient tablet form.